Overview

A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321

Status:
Completed
Trial end date:
2020-11-25
Target enrollment:
Participant gender:
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 706321 in healthy male and female subjects following oral administration of multiple rising doses for 14 days.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Midazolam